Metabolic Research

Survodutide

InvestigationalWeight & metabolic
5.1/10

BioHarmony verdict

Neutral

Survodutide (BI 456906) is an investigational once-weekly GLP-1 and glucagon dual agonist that drove up to 16.6% weight loss in Phase 3, per the Boehringer Ingelheim SYNCHRONIZE-1 topline, and 62% liver-disease improvement on its best Phase 2 dose, per Sanyal 2024.

Read full report

What is Survodutide?

Survodutide, also called BI 456906, is an investigational injectable peptide that hits two receptors at once: GLP-1 and glucagon. The GLP-1 arm is the familiar one. It blunts appetite and slows the stomach, the same way semaglutide does. The glucagon arm is the twist. It tells the liver to burn its own fat and adds a little extra heat production on top.

From the BioHarmony report, reviewed 2026-09-08.

How it is thought to work

GLP-1 arm cuts appetite and slows the gut; glucagon arm burns liver fat and adds thermogenesis

Safety watch-outs

  • Severe, persistent stomach pain that may travel to the back (possible pancreatitis): stop and seek care.
  • Relentless vomiting with signs of dehydration: stop and consult a clinician.
  • New or worsening fast or irregular heartbeat: reduce dose or stop and get evaluated.
  • Any personal or family history of medullary thyroid cancer or MEN 2: do not use, consistent with the GLP-1 class warning.

Full risk profile in the BioHarmony report.

Dosing as published

No approved-label or study protocol is recorded for Survodutide yet.

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Trust & sourcing

US approvalInvestigational
CompoundingNo FDA-approved product; compounding eligibility is not established
Last checked2026-09-02
Next review2026-10-02 (overdue, details paused)

Primary sources

Sources are still being reviewed for this compound.

  1. 6.5/10MOTS-cWorth tryingWeight & metabolicNot FDA approvedMOTS-c is a 16-amino-acid mitochondrial-derived peptide discovered in Lee 2015 that activates AMPK through the folate and purine pathway.
  2. 6.2/10IpamorelinWorth tryingRecoveryNot FDA approvedIpamorelin is a selective growth-hormone secretagogue with strong receptor selectivity but almost no human efficacy data: its only completed human efficacy trial…
  3. 6.1/10TirzepatideWorth tryingWeight & metabolicFDA-approved product existsTirzepatide is a once-weekly subcutaneous dual GIP plus GLP-1 receptor agonist with unusually large weight-loss and glycemic effects.
  4. 6.0/10Semaglutide (GLP-1 Agonist)Worth tryingWeight & metabolicFDA-approved product existsSemaglutide is a prescription GLP-1 receptor agonist that produced 14.9% mean weight loss in STEP-1 and cut 3-point MACE by 20% in SELECT, but the 6.0-6.5/10 score holds…

Free guide

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.